

Supplemental Tables

Supplemental Table 1: Search strategy.

Supplemental Table 2: Management of possible confounders.

Supplemental Table 3: Factors for subgroups analysis.

Supplemental Table 4: Subgroup analyses for PTB.

Supplemental Table 5: Subgroup analyses for LBW.

Supplemental Table 6: Subgroup analyses for SGA.

Supplemental Table 7: Sensitive analyses and publication bias for APOs.

Supplemental Table 1: Search strategy.

#1	TS=(“Oral Health [mh]” OR “Oral Disease” OR “Periodontal Diseases [mh]” OR “PD” OR “Periodontitis [mh]” OR “Periodontitides” OR “Gingivitis [mh]” OR “Gingivitides” OR “Gingival Disease” OR “Gingivosis”)
#2	TS=(“Pregnancy Outcome [mh]” OR “Obstetrical Disorder” OR “Obstetrical Diseases” OR “Premature Birth [mh]” OR “Infant, Premature” OR “Preterm Birth” OR “PTB” OR “Premature Delivery” OR “Preterm Delivery” OR “PTD” OR “Infant, Low Birth Weight [mh]” OR “Low Birth Weight” OR “LBW” OR “Infant, Small for Gestational Age [mh]” OR “Small for Gestational Age” OR “SGA”)
#1 AND #2	

Unless otherwise declared, terms used in search strategy were free text terms.

TS, topic.

Supplemental Table 2: Management of possible confounders.

Author/Year	Age	BMI	Ethnicity	Parity	Smoking	Alcohol	Drug abuse	History of events ^a	Pregenancy Complication ^b	Genitourinary tract infection ^c	Marital status	Education	Socioeconomic	Prenatal care	PD treatment
Agueda <i>et al.</i> 2008	A	N	A	NR	A	N	E	A	A	A	NR	N	N	A	NR
Baskaradoss <i>et al.</i> 2011	A	N	NR	N	N	NR	NR	A	N	A	NR	N	N	N	E
Bassini <i>et al.</i> 2007	A	NR	N	N	A	N	NR	A	A	A	NR	N	N	A	NR
Bogges <i>et al.</i> 2006	A	N	N	NR	A	N	A	N	A	N	A	NR	N	NR	NR
Cruz <i>et al.</i> 2005	N	NR	NR	NR	N	N	NR	NR	NR	A	N	N	N	N	E
Erchick <i>et al.</i> 2020	N	N	N	N	N	NR	NR	NR	NR	N	E	N	N	NR	NR
Filho <i>et al.</i> 2016	A	A	N	A	N	N	NR	N	NR	N	NR	NR	A	A	E
Jacob <i>et al.</i> 2014	N	NR	NR	E	A	NR	NR	NR	A	A	NR	N	A	A	E
Khan <i>et al.</i> 2016	NR	NR	NR	E	N	NR	NR	NR	E	E	NR	A	A	N	E
Kumar <i>et al.</i> 2013	A	A	NR	E	NR	NR	NR	NR	N	E	NR	A	A	NR	E
Macedo <i>et al.</i> 2014	N	NR	N	N	E	E	E	N	NR	N	N	N	N	N	N
Mathew <i>et al.</i> 2014	A	NR	NR	N	N	NR	NR	N	E	N	A	N	N	N	E
Micu <i>et al.</i> 2020	N	N	NR	N	A	NR	NR	N	E	E	NR	N	N	N	E
Moore <i>et al.</i> 2004	A	NR	N	N	N	N	NR	N	N	N	NR	NR	N	NR	N
Nabet <i>et al.</i> 2010	A	A	A	A	A	NR	N	NR	N	NR	A	A	N	N	NR
Novak <i>et al.</i> 2020	N	NR	NR	N	A	NR	NR	NR	E	E	NR	A	A	NR	E
Offenbacher <i>et al.</i> 2006	A	NR	A	A	A	N	N	A	A	N	A	NR	A	NR	NR
Pitiphat <i>et al.</i> 2008	A	A	A	A	A	N	NR	A	NR	A	N	N	A	NR	NR
Ryu <i>et al.</i> 2010	A	NR	NR	A	A	A	NR	A	NR	NR	NR	NR	NR	NR	N

Saddki <i>et al.</i> 2008	N	N	NR	N	N	E	NR	N	NR	NR	NR	A	N	N	E
Souza <i>et al.</i> 2016	A	A	N	A	A	NR	NR	N	A	N	N	A	N	A	E
Tejada <i>et al.</i> 2012	NR	NR	NR	N	N	NR	NR	N	E	A	A	NR	A	N	N
Turton <i>et al.</i> 2017	N	NR	N	NR	E	E	NR	NR	NR	NR	NR	N	NR	NR	NR
Vogt <i>et al.</i> 2010	N	N	N	N	N	N	NR	E	NR	N	N	N	NR	A	NR

A: adjusted confounder; N: unadjusted confounder; NR: not reported; E: confounder as excluded criteria; BMI: Body Mass Index;

^a whether recorded early events of PTB and/or LBW and/or SGA

^b whether recorded pregnancy complication such as preeclampsia and/or pregnancy-induced hypertension and/or gestational diabetes mellitus

^c whether recorded genitourinary tract infection and/or chorioamnionitis

Supplemental Table 3: Factors for subgroups analysis.

Outcomes	Region	Design	Criteria	NOS quality	Adjusted Age	Adjusted GTI
PTB	Asia	Prospective cohort	Lopez	High	Yes	Yes
	Europe		CDC-APP			
	South America		Offenbacher			
	North America		Other			
	Africa					
LBW	Asia	Prospective cohort	Lopez	High	Yes	Yes
	Europe		WHO			
	South America		Offenbacher			
	Africa		Other			
SGA	Asia	NA	WHO	High	Yes	Yes
	South America		Other			
	North America					

NS: No significant result was observed in any subgroup;

NA: Subgroup analyses were not available;

Supplemental Table 4: Subgroup analyses for PTB.

	No. of studies	OR (95% CI)	<i>P</i>	Weight (%)	Q	<i>Ph</i>	<i>I</i> ² (%)
All studies	15	1.57 [1.39, 1.77]	0.000	100	15.20	0.364	7.9
Region							
Asia	4	1.31 [1.04, 1.64]	0.021	31.63	2.52	0.472	0.0
Europe	6	1.52 [1.27, 1.82]	0.000	47.10	4.67	0.457	0.0
South America	2	1.88 [1.13, 3.12]	0.015	5.17	0.06	0.799	0.0
North America	2	1.96 [1.36, 2.84]	0.000	10.72	0.9	0.342	0.0
Africa	1	2.42 [1.47, 4.00]	0.001	5.38			
Design							
Prospective cohort	8	1.57 [1.33, 1.86]	0.000	53.45	10.27	0.174	31.8
Case-control	7	1.56 [1.30, 1.87]	0.000	46.55	4.95	0.551	0.0
Criteria							
Lopez	5	1.50 [1.24, 1.83]	0.000	39.97	3.33	0.504	0.0
CDC-APP	2	1.70 [1.14, 2.52]	0.009	8.94	0.51	0.475	0.0
Offenbacher	2	2.22 [1.62, 3.04]	0.000	14.37	0.19	0.661	0.0
Other	6	1.35 [1.10, 1.67]	0.005	36.72	4.29	0.509	0.0
NOS quality							
High	6	1.94 [1.58, 2.39]	0.000	32.65	3.01	0.698	0.0
Low	9	1.39 [1.19, 1.62]	0.000	67.35	6.06	0.641	0.0

Adjusted age							
Yes	8	1.51 [1.28, 1.77]	0.000	59.03	5.44	0.606	0.0
No	7	1.65 [1.37, 1.99]	0.000	40.97	9.26	0.160	35.2
Adjusted GTI							
Yes	6	1.86 [1.47, 2.35]	0.000	23.26	1.06	0.958	0.0
No	9	1.48 [1.28, 1.71]	0.000	76.74	11.41	0.180	29.9

GTI: genitourinary tract infection

Supplemental Table 5: Subgroup analyses for LBW.

	No. of studies	OR (95% CI)	<i>P</i>	Weight (%)	<i>Q</i>	<i>Ph</i>	<i>I</i> ² (%)
All studies	14	2.43 [1.75, 3.37]	0.0000	100.00	72.50	0.000	82.1
Region							
Asia	5	3.06 [2.10, 4.47]	0.000	32.75	6.71	0.152	40.3
Europe	3	1.74 [1.02, 2.97]	0.044	22.51	5.30	0.171	62.2
South America	5	1.74 [1.03, 2.94]	0.038	39.57	27.27	0.000	85.3
Africa	1	14.74 [5.30, 41.00]	0.000	5.17			
Design							
Prospective cohort	6	2.48 [1.37, 4.51]	0.003	41.33	25.70	0.000	80.5
Case-control	8	2.37 [1.49, 3.76]	0.000	58.67	47.26	0.000	85.2
Criteria							
Lopez	2	1.87 [1.33, 2.64]	0.000	15.99	0.60	0.440	0.0
WHO	2	3.28 [2.26, 4.77]	0.000	15.16	0.72	0.397	0.0
Offenbacher	1	14.74 [5.30, 41.00]	0.001	5.17			
Other	9	2.00 [1.32, 3.04]	0.000	63.68	42.02	0.000	81.0
NOS quality							
High	7	2.80 [1.56, 5.04]	0.001	50.25	43.34	0.000	86.2
Low	7	2.10 [1.34, 3.30]	0.001	49.75	29.37	0.000	79.6
Adjusted age							

Yes	7	1.92 [1.24, 2.97]	0.003	51.60	32.90	0.000	81.8
No	7	2.99 [1.80, 4.95]	0.000	48.40	25.91	0.000	76.8
Adjusted GTI							
Yes	7	2.14 [1.52, 3.02]	0.000	55.32	22.75	0.001	73.6
No	7	2.87 [1.36, 6.09]	0.006	44.68	50.36	0.000	88.1

GTI: genitourinary tract infection

Supplemental Table 6: Subgroup analyses for SGA.

	No. of studies	OR (95% CI)	<i>P</i>	Weight (%)	<i>Q</i>	<i>Ph</i>	<i>I</i> ² (%)
All studies	4	1.62 [0.86, 3.07]	0.136	100	7.06	0.07	57.5
Region							
Asia	1	0.74 [0.36, 1.52]	0.412	28.05			
South America	1	2.50 [0.93, 6.75]	0.070	21.25			
North America	2	2.18 [1.23, 3.85]	0.007	50.69	0.75	0.388	0.0
Criteria							
WHO	1	2.63 [1.28, 5.37]	0.008	28.25			
Other	3	1.34 [0.65, 2.78]	0.434	71.75	4.13	0.127	51.6
NOS quality							
High	2	1.39 [0.40, 4.88]	0.603	56.30	6.07	0.014	83.5
Low	2	1.96 [0.99, 3.88]	0.054	43.70	0.45	0.505	0.0
Adjusted age							
Yes	3	1.45 [0.65, 3.19]	0.362	78.75	6.09	0.048	67.1
No	1	2.50 [0.93, 6.75]	0.070	21.25			
Adjusted GTI							
Yes	2	1.01 [0.49, 2.11]	0.971	50.50	1.57	0.210	36.3
No	2	2.58 [1.44, 4.62]	0.001	49.50	0.01	0.937	0.0

GTI: genitourinary tract infection

Supplemental Table 7: Sensitive analyses and publication bias for adverse pregnancy outcomes

Outcome	No. of Studies	Effects Model	Variations in	Egger's Test for Publication Bias (<i>P</i>)	Variations in Trim
			Sensitivity Analyses		and Filled Analyses
			OR (95%CI)		OR (95%CI)
PTB	15	fixed	NS	0.063	-
LBW	14	random	NS	0.006	-
SGA	4	random	NS	0.699	-

NS: No significant variations introduce